Core Scientific (CORZW) Liabilities and Shareholders Equity (2020 - 2026)

Core Scientific has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $5.3 billion in Q2 2026.

• Quarterly Liabilities and Shareholders Equity rose 184.08% year-over-year to $5.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $12.8 billion (up 127.39% YoY) and the FY2025 annual result came in at $2.3 billion, up 59.06% from the prior year.
• Liabilities and Shareholders Equity advanced to $5.3 billion in Q2 2026 per CORZW's latest filing, from $3.1 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $5.3 billion in Q2 2026 and troughed at $664.2 million in Q2 2024.
• A 5-year average of $1.6 billion and a median of $1.4 billion in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity soared 677.6% in 2022, then tumbled 71.89% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $807.7 million in 2022, then declined by 11.83% to $712.2 million in 2023, then jumped by 107.25% to $1.5 billion in 2024, then soared by 59.06% to $2.3 billion in 2025, then soared by 123.95% to $5.3 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $5.3 billion, $3.1 billion, and $2.3 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.